Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Paragraph: Becerra was discussing the findings of a 147-page report prepared by his office that also found that detainees face long periods of confinement without breaks and language barriers in the 10 detention facilities state authorities inspected in 2017. Becerra said the annual report released Tuesday is the first of 10 that the state Legislature requires of the California Department of Justice, which is tasked with inspecting all federal immigration detention facilities in the state. That law was one of three immigration-related "sanctuary state" bills passed in 2017 that the Trump administration unsuccessfully challenged in court. Inspectors spent one day on scheduled visits at 10 facilities in operation in 2017. ICE contracted with four for-profit prison companies and six county sheriffs to house and care for the inmates. Since then and amid growing protests, sheriffs in Sacramento and Contra Costa counties terminated their contracts with ICE to house federal immigration inmates in the local jails. A third facility near Bakersfield is also facing closure after the city of McFarland told ICE it would not renew its contract when it expires in March. Becerra said many of the problems are caused by inadequate federal oversight. He said a common "challenge" inspectors found at most facilities included confining inmates to their cells for up to 22 hours a day. He noted that most of the detainees are not accused of crimes and are awaiting court decisions on their immigration status. ICE spokeswoman Lori Haley said the private prison companies and county jails that house detainees "must meet rigorous performance standards." "The safety, rights and health of detainees in ICE's care are of paramount concern and all ICE detention facilities are subject to stringent, regular inspections," Haley said. The attorney general's report estimated that 74,000 immigrant detainees have been held in California detention centers over a three-year period ending in 2017 with an average stay of 50 days per inmate. Becerra said the state inspections of federal immigration facilities in California were necessary "because everyone in this country has constitutional rights and everyone at the end of the day child and adult deserve to be treated in a human way." In a separate report , California's state auditor Elaine Howle said cities and counties failed to properly monitor the facilities in their locales. Howle's report also called on ICE to be more transparent in its detention operations. "The state lacks complete information about how much it costs and what conditions the detainees face," Howle's report concluded. "Also unclear are how many detainees are being held throughout California, where they are being held, and for how long." Claim: California officials: Immigration facilities lack oversight.
Detainees confined to federal immigration detention facilities located in California have inadequate access to health care, lawyers and family, state Attorney General Xavier Becerra said Tuesday.

Paragraph: "Ed Stafford of Leicestershire, England walks in between trees as he walks through the Amazon jungle in Brazil in this undated handout photo. Former British army captain Stafford became on Monday the first known person to walk from the origin of the Amazon river, the world's second-longest river, to its mouth, after withstanding ""50,000"" mosquito bites, scorpion attacks and skin disease in his 859 day odyssey. REUTERS/Handout Ed Stafford, a 34-year-old from Leicestershire, England, dived into the Atlantic Ocean after taking 859 days to walk the length of the world's second-longest river, starting at the peak of Mount Mismi in Peru in April 2008. "It's just phenomenal to be here at the end of the journey after 2-1/2 years slogging our way through the jungle," he told Reuters after arriving at the beach about 90 miles northeast of the Brazilian city of Belem. "It was really difficult to envisage how this was going to feel and I'm completely overwhelmed." Stafford briefly collapsed from exhaustion with only 52 miles of the 6,000-mile journey to go, passing out by the roadside after breaking out in a rash. "I feel slightly humbled that my system just decided to shut down so close to the finish," he wrote on his blog at www.walkingtheamazon.com. Stafford has aimed to use the walk to raise awareness about the threats to the Amazon rain forest and its people, using a portable satellite video to blog about his trek. He had planned to complete the walk in about a year, but the journey was prolonged by floods that forced him to walk a roundabout route that was 2,000 miles longer than the 4,000-mile (6,400-km) length of the Amazon, which is exceeded in length only by Africa's Nile river. He began the journey with fellow British adventurer Luke Collyer, but the pair had a falling out early in the trek and Stafford continued alone. He was joined in July 2008 by a Peruvian forestry worker, Gadiel Cho Sanchez Rivera, who pledged to walk with him for five days and has been with him on the walk ever since. A statement from Stafford's media team said that the Briton had been: "wrongly accused of murder on two separate occasions, been imprisoned, had concrete stuffed in his mouth by hostile tribes people, been chased by Ashaninka Indians with bows and arrows, been stung by hundreds of wasps and watched as his guide 'Cho' removed a botfly from Ed's head with superglue and a tree spine." It said he had endured "50,000" mosquito bites, lived on a diet of piranha fish, rice and beans, and dodged a variety of snakes, electric eels, scorpions, and ants, as well as contracting a skin-disfiguring disease. Famed British explorer Sir Ranulph Fiennes was quoted as saying in the statement that Stafford's feat was "truly extraordinary." "No one has ever done this before and the pundits considered the route impossible," he said." Claim: British man becomes first to walk Amazon length.
A former British army captain became on Monday the first known person to walk from the origin of the Amazon river to its mouth, after enduring "50,000" mosquito bites, attacks by hostile Indians and tropical disease in his nearly 2-1/2 year odyssey.

Paragraph: The news release does not bring up costs, but we'll rate this Not Applicable since the release is clear that this is early-stage work that is not yet ready for use in humans. Some mention of costs would have been valuable nonetheless. Gene therapy is known to be extremely costly, and when a disease is rare, as this is, that raises questions about what company would find it profitable to pursue the potential treatment. The University of Utah provides some excellent background on the "commercial viability" of gene therapy. The release squeaks by on this. There are no numbers used to quantify, but this excerpt at least touches on the method of measurement and the three-year follow up. "The treated dogs had expressed levels of clotting factor VII that would be therapeutic in humans, with long-term stability. In one dog, the effects persisted nearly three years." The release could have explained whata "therapeutic" expression level of clotting factor actually means. A closer look at the paper reveals that a clinically therapeutic level is greater than or equal to 15% of normal. The release addresses harms in a couple of places, as in this excerpt: "The FVII-deficient dogs tolerated the initial gene therapy infusions very well and have had no adverse side effects over several years of follow up." and in a quote by the lead researcher: "Based on kidney function, liver function, and blood measurements in the dogs, the treatment was safe, and did not elicit unwanted immune responses." But as this study was done in canines, we would have liked a bit more detail on how harms might manifest in human clinical trials. The limited information given in the news release describes the quality of the evidence, particularly the fact that this was an animal study that is not directly applicable to humans. The release notes that the study "sets the stage for clinical trials in humans." The release could have noted thata study with only four (canine) participants is very small. There is no disease mongering. There were no conflicts identified. All the funding sources were listed. The release tells us that this rare clotting disorder is currently treated by infusions of clotting factors. The release could have done a better job of explaining how difficult that therapy is for patients. Is the disorder regulated well by that method? We aren't given any information or what those costs are vs. what a one-time gene therapy might cost. The release makes clear that this treatment will not be available until human clinical trials are conducted. This gene therapy is novel for this particular condition. The news release should also be commended for pointing out that a similar gene therapy approach has been tested by the same researchers for hemophilia. It's admirable that they are not overselling the novelty of this approach by referencing their own previous work in related areas. We were pleased to see proof-of-concept in the headline, because this is a very useful way to immediately alert readers that an idea has been validated, but not a therapy for human patients. Claim: Gene therapy for rare bleeding disorder achieves proof-of-concept
Credit: UC Davis Comparative Oncology ProgramThis short news release describes a gene therapy experiment in four dogs that might turn out to help human patients with a rare blood disorder known as Factor VII deficiency. The release does a good job of making clear that this is just a proof-of-concept and needs human trials. Great specific language is used to make that clear. But it does not give any context for the problems of developing gene therapies for rare diseases. Companies may balk at developing a treatment than can't be sold very widely, which contributes to high costs. Gene therapies are emotional minefields for patients and families, especially since so much has been promised and actual successes have been few. One gene therapy offered in Europe has a price tag of $1 million. This release would serve readers better if it gave some of that daunting context. A Washington Post story explains some of the challenges: "No [gene] therapy is approved yet in the United States, so discussions about price as well as crucial questions about how much patients will pay directly are hypothetical. But industry leaders are already talking about ways to get ahead of potentially massive one-time price tags that could make insurers and patients balk."